Ticker >

Shilpa Medicare share price

Shilpa Medicare Ltd.

NSE: SHILPAMED BSE: 530549 SECTOR: Pharmaceuticals & Drugs  40k   168   24

355.30
+3.85 (1.10%)
NSE: 22 Sep 03:59 PM

Price Summary

Today's High

₹ 357

Today's Low

₹ 346.3

52 Week High

₹ 399.95

52 Week Low

₹ 222.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

3084.07 Cr.

Enterprise Value

3366.66 Cr.

No. of Shares

8.68 Cr.

P/E

0

P/B

1.45

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  244.87

CASH

4.83 Cr.

DEBT

287.42 Cr.

Promoter Holding

50.01 %

EPS (TTM)

₹  -5.23

Sales Growth

-30.61%

ROE

-2.37 %

ROCE

-1.61%

Profit Growth

-345.47 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-30.61%
3 Year-32.52%
5 Year-19.69%

Profit Growth

1 Year-59.43%
3 Year-33.41%
5 Year-15.56%

ROE%

1 Year-2.37%
3 Year0.98%
5 Year5.27%

ROCE %

1 Year-1.61%
3 Year1.56%
5 Year6.07%

Debt/Equity

0.1357

Price to Cash Flow

1482.01

Interest Cover Ratio

-1.79835390946502

CFO/PAT (5 Yr. Avg.)

1.58819609146429

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2023 50.01 12.9
Mar 2023 50.01 12.9
Dec 2022 50.01 1.38
Sep 2022 50.01 0.81
Jun 2022 50.01 0.81
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 2.63022082742868.

 Limitations

  • The company has shown a poor profit growth of -166.509178353462% for the Past 3 years.
  • The company has shown a poor revenue growth of -32.5156066864718% for the Past 3 years.
  • Company has a poor ROE of 0.97810300441596% over the past 3 years.
  • Company has a poor ROCE of 1.55616268817415% over the past 3 years
  • Company has low Interest coverage ratio of -1.79835390946502.
  • Company has contingent liabilities of 510.0491 Cr.
  • The company is trading at a high EV/EBITDA of 77.2627.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023
Net Sales 60.83 68.73 51.64 66.5 83.74
Total Expenditure 56.33 93.21 61.9 80.27 68.4
Operating Profit 4.5 -24.48 -10.26 -13.77 15.34
Other Income 12.63 18.09 17.6 20.33 20.78
Interest 2.66 4.92 6.64 6.61 6.76
Depreciation 10.42 11.89 12.26 11.98 12.26
Exceptional Items 0 -0.59 0 -14.96 -6.34
Profit Before Tax 4.05 -23.78 -11.56 -26.99 10.76
Tax 0.2 -4.16 -6.77 1.94 2.86
Profit After Tax 3.85 -19.63 -4.79 -28.93 7.9
Adjusted EPS (Rs) 0.44 -2.26 -0.55 -3.33 0.91

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 663.88 805.97 257.05 356.95 247.7
Total Expenditure 476.96 568.18 228.58 345.93 302.88
Operating Profit 186.92 237.79 28.47 11.02 -55.17
Other Income 17.16 18.37 37.14 51.52 79.82
Interest 2.79 4.33 6.07 9.05 20.83
Depreciation 34.01 34.96 22.28 34.82 46.55
Exceptional Items 6.22 -4.54 52.95 8.81 -15.55
Profit Before Tax 173.5 212.34 90.21 27.49 -58.28
Tax 37.75 44.15 25.12 7.33 -8.79
Net Profit 124.11 193.72 184.39 140.99 57.19
Adjusted EPS (Rs.) 16.65 20.63 7.98 2.32 -5.7

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 8.15 8.15 8.15 8.68 8.68
Total Reserves 1273.39 1445.27 1629.68 2056.99 2108.9
Borrowings 81.1 164.48 324.52 120.28 122.8
Other N/C liabilities 76.06 43.52 81.06 89.87 35.56
Current liabilities 229.59 359.86 473.98 161.65 241.41
Total Liabilities 1668.29 2021.28 2517.39 2896.12 2517.36
Assets
Net Block 510.84 517 640.9 565.78 608.93
Capital WIP 284.8 244.18 297.19 52.57 41.84
Intangible WIP 116.41 128.63 185.16 240.55 184.59
Investments 89.04 93.48 219.32 237.5 243.92
Loans & Advances 119.95 124.54 391.84 595.14 802.92
Other N/C Assets 26.83 5.76 3.1 895.15 0.2
Current Assets 520.42 907.69 779.9 309.44 634.95
Total Assets 1668.29 2021.28 2517.39 2896.12 2517.36
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 155.6 233.99 255.54 192.89 12.68
Adjustment 25.78 -5.39 -25.46 32.64 -35.56
Changes in Assets & Liabilities 18.23 -57.95 -117.1 -17.17 33.37
Tax Paid -35.45 -40.85 -43.34 -34.49 -8.41
Operating Cash Flow 164.16 129.79 69.63 173.87 2.08
Investing Cash Flow -214.71 -302.49 -238.13 -378.97 -94.8
Financing Cash Flow 8.17 170.1 255.58 97.23 87.68
Net Cash Flow -42.38 -2.59 87.08 -107.88 -5.04

Corporate Actions

Investors Details

PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
promoters 50.01 50.01 50.01 50.01 50.01
brijgopal innani 1.35 1.35 1.35 1.35 1.35
deepak kumar innani 3.15 3.15 3.15 3.15 3.15
dharmavati bhutada 7.15 7.15 7.15 7.15 7.15
kamalkishore innani 0.19 0.19 0.19 0.19 0.19
kantadevi inani 2.93 2.93 2.93 2.93 2.93
keerti innani 0.18 0.18 0.18 0.18 0.18
keshav bhutada 2.30 2.30 2.30 2.30 2.30
madhav vishnukant bhutada... 2.30 2.30 2.30 2.30 2.30
manjulatha innani 0.18 0.18 0.18 0.18 0.18
namrata bhutada 0.03 0.03 0.03 0.03 0.03
natamal innani 1.30 1.30 1.30 1.30 1.30
om prakash inani 3.30 3.30 3.30 3.30 3.30
priya innani 0.21 0.21 0.21 0.21 0.21
ramakant innani 1.73 1.73 1.73 1.73 1.73
ravi kumar innani 4.62 4.62 4.62 4.62 4.62
sagar innani 1.15 1.15 1.15 1.15 1.15
shakuntalabai innani 1.30 1.30 1.30 1.30 1.30
suraj kumar innani 4.59 4.59 4.59 4.59 4.59
taradevi innani 1.44 1.44 1.44 1.44 1.44
triveni inani 0.34 0.34 0.34 0.34 0.34
vishnukant chaturbhuj bhu... 7.33 7.33 7.33 7.33 7.33
vishnukanta inani 1.40 1.40 1.40 1.40 1.40
vishnukanth c bhutada (hu... 1.54 1.54 1.54 1.54 1.54
PARTICULARS Jun 2022% Sep 2022% Dec 2022% Mar 2023% Jun 2023%
investors 49.99 49.99 49.99 49.99 49.99
akash bhanshali - - - 1.84 1.84
amal n parikh - - 1.95 1.95 1.95
india opportunities growt... - - - - 1.08
investor education and pr... - - - 0.33 0.30
malabar select fund 1.80 1.80 1.80 1.80 1.22
pivotal enterprises priva... 2.53 - 2.53 2.53 2.53
ta fii investors limited 3.48 - 3.48 3.48 3.48
india opportunities growt... 1.19 1.19 1.66 1.08 -
karthik sundar - - - 1.14 -
malabar india fund limite... 1.58 1.58 1.58 1.58 -
think india opportunities... 2.02 2.02 2.02 2.02 -
blue daimond properties p... - - 1.84 - -
investor education and pr... - - 0.33 - -
sundar iyer 1.15 1.15 1.14 - -
anandkumar ramesh gupta 1.08 1.08 - - -
blue daimond properties p... 1.84 - - - -
iepf 0.33 - - - -
pivotal business managers... 2.12 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • ConcallQ4FY23 5 Jun 2023
  • PresentationQ4FY23 26 May 2023
  • PresentationQ4FY21 1 Jun 2021
  • PresentationQ4FY21 1 Jun 2021
  • PresentationQ4FY20 20 Jun 2020
  • PresentationQ3FY23 1 Mar 2023
  • PresentationQ3FY22 11 Feb 2022
  • PresentationQ1FY21 11 Aug 2020

Company News

Shilpa Medicare gets marketing authorization for Betahistine Dihydrochloride Orodispersible Films4 Sep 2023, 11:52AM Shilpa Medicare’s finished dosage form manufacturing facility clears GMP inspection by ANVISA, Brazil25 Aug 2023, 2:42PM Shilpa Medicare informs about disclosure19 Aug 2023, 2:11PM Shilpa Medicare - Quaterly Results10 Aug 2023, 2:18PM Shilpa Medicare - Quaterly Results10 Aug 2023, 2:18PM Shilpa Medicare - Quaterly Results10 Aug 2023, 2:18PM Shilpa Medicare informs about disclosure9 Aug 2023, 3:06PM Shilpa Medicare informs about disclosure 4 Jul 2023, 12:43PM Shilpa Medicare gets nod to manufacture, sale Lenvatinib Capsules of higher strengths30 Jun 2023, 11:40AM Shilpa Medicare’s arm gets marketing authorization permission for Adalimumab injection30 Jun 2023, 10:20AM Shilpa Medicare informs about conference call25 May 2023, 5:18PM Shilpa Medicare - Quaterly Results25 May 2023, 3:55PM Shilpa Medicare - Quaterly Results25 May 2023, 3:55PM Shilpa Medicare - Quaterly Results25 May 2023, 3:55PM Shilpa Medicare gets USFDA’s approval for New Drug Application for Pemetrexed Injection23 May 2023, 3:39PM Shilpa Medicare informs about disclosure26 Apr 2023, 2:37PM Shilpa Medicare gets USFDA’s final nod for Apremilast Tablets11 Apr 2023, 9:24AM Shilpa Medicare informs about credit rating28 Mar 2023, 4:45PM USFDA inspects Shilpa Medicare’s Analytical Services Division in Hyderabad11 Mar 2023, 4:52PM Shilpa Medicare informs about inspection11 Mar 2023, 12:01PM Shilpa Medicare - Quaterly Results14 Feb 2023, 4:24PM Shilpa Medicare - Quaterly Results14 Feb 2023, 4:24PM Shilpa Medicare - Quaterly Results14 Feb 2023, 4:24PM Shilpa Medicare introduces Capecitabine 1000 MG dispersible tablet17 Dec 2022, 4:27PM Shilpa Medicare’s Telangana facility gets Health Canada GMP approval1 Dec 2022, 4:11PM Shilpa Medicare submits related party transactions24 Nov 2022, 10:51AM Shilpa Medicare informs about analyst meet 21 Nov 2022, 4:59PM Shilpa Medicare informs about disclosure21 Nov 2022, 2:20PM Shilpa Medicare - Quaterly Results11 Nov 2022, 5:10PM Shilpa Medicare - Quaterly Results11 Nov 2022, 5:10PM Shilpa Medicare informs about disclosure 27 Oct 2022, 4:28PM Shilpa Medicare informs about compliance certificate15 Oct 2022, 4:21PM Shilpa Medicare’s Analytical Services division gets USFDA’s clearance 22 Sep 2022, 5:26PM Shilpa Medicare gets CDSCO approval for hemostatic spray of Tranexamic Acid20 Sep 2022, 12:16PM Shilpa Medicare informs about approval for tablets16 Sep 2022, 3:14PM Shilpa Medicare gets USFDA’s nod for Tenofovir Alafenamide tablets16 Sep 2022, 2:29PM Shilpa Medicare informs about audio recording of conference call 25 Aug 2022, 12:19PM Shilpa Medicare’s arm completes Human Clinical studies of High concentration Biosimilar Adalimumab 19 Aug 2022, 4:00PM Shilpa Medicare - Quaterly Results11 Aug 2022, 6:46PM Shilpa Medicare - Quaterly Results11 Aug 2022, 6:46PM Shilpa Medicare’s Bengaluru unit clears USFDA remote record review29 Jul 2022, 4:42PM Shilpa Medicare gets GMP certificate from MOH-Russia for API facility in Karnataka18 Jul 2022, 10:01AM Shilpa Medicare gets GMP Certificate from UK MHRA for Bengaluru facility 12 Jul 2022, 4:57PM Shilpa Medicare executes transfer agreement with Shilpa Pharma Lifesciences4 Jul 2022, 9:22AM Shilpa Medicare - Quaterly Results23 May 2022, 4:35PM Shilpa Medicare - Quaterly Results23 May 2022, 4:35PM Shilpa Medicare - Quaterly Results23 May 2022, 4:35PM USFDA inspects Shilpa Medicare’s Analytical Services Division in Telangana2 May 2022, 4:30PM Shilpa Medicare gets NoC from RCGM for Biosimilar Aflibercept 26 Apr 2022, 10:49AM Shilpa Medicare informs about company updates25 Apr 2022, 2:33PM

Shilpa Medicare Stock Price Analysis and Quick Research Report. Is Shilpa Medicare an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Shilpa Medicare and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2.081 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Shilpa Medicare has a Debt to Equity ratio of 0.1357 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Shilpa Medicare , the EPS growth was -345.476467295354 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Shilpa Medicare has OPM of -22.2744668997424 % which is a bad sign for profitability.
     
  • ROE: Shilpa Medicare have a poor ROE of -2.36576722443531 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Last Updated on:
Brief about Shilpa Medicare
X